 Dinaciclib is being developed by Merck & Co.It was granted orphan drug status by the FDA in 2011.In primary cultured neurons, dinaciclib regulates neurogenesis, where it reduces expression of upper layer marker Satb2, and induces CTIP2, expressed in neurons of deeper layers.